IMMUNIC THERAPEUTICS Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | March 2021 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, pla ...

IMMUNIC THERAPEUTICS Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | October 2020 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, p ...

Immunic, Inc. (NASDAQ:IMUX) Q2 2020 Earnings Conference Call August 3, 2020 8:30 AM ET Â Company Participants Jessica Breu - Head of Investor Relations and Communications Dr. Daniel Vitt - CEO, President and Director Dr. Andreas Muehler - Chief Medical Officer Conference Call Participants Liana Moussatos - Wedbush Pacgrow Healthcare Matthew Kaplan - Ladenburg Thalmann & Co. Inc. George Farmer - BMO Capital Markets Corp Yasmeen Rahimi - Piper Sandler Raghuram Selvaraju - H.C. Wainwright & Co. Zegbeh Jallah - ...

Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | June 2020 Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management's intentions, plans, bel ...

| --- | --- | |-------|---------------------------------------------------------------------| | | | | | | | | | | | | | | Immunic Therapeutics Developing Selective Oral Drugs in Immunology | | | NASDAQ: IMUX February 2020 | Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Privat ...

Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX Piper Jaffray 31st Annual Healthcare Conference December 5, 2019 Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include s ...

| --- | --- | |--------------------|-----------------------------------------------------------------------------------| | | | | | | | | | | | Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | | Ladenburg Thalmann | Healthcare Conference September 24, 2019 | Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of ...

| --- | --- | |-------|-----------------------------------------------------------------------------| | | | | | | | | | | | | | | Immunic Therapeutics Developing Selective Oral Drugs in Immunology | | | NASDAQ: IMUX 39th Annual Canaccord Genuity Growth Conference August 8, 2019 | Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securi ...